Biobanking Containment Genetics Genome 
pharmaphorum
JANUARY 18, 2023
In 2016, scientists behind a study called the Resilience Project analysed genetic data from 589,000+ people and found 13 adults who carried genetic variants that should have resulted in serious – even deadly – childhood disease, but who were apparently healthy. Giving participants something in return.
Drug Discovery World
MARCH 7, 2023
As such, Qatar Biobank has emerged within this modernisation to act as a focal point for the country’s goal in preventive and personalised healthcare. It also fits with the country’s preventative health approach that it established in its 2017-2022 Public Health Strategy 5.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
FEBRUARY 4, 2021
The power of leveraging clinical data to decipher disease mechanisms and fuel drug discovery has rapidly grown in the era of genomics and personalized medicine. Biobanks are used for the coordination of high-yield patient sample collection. Generation of strong research dataset cohorts must begin with high-quality clinical samples.
XTalks
APRIL 15, 2021
New advances in heart failure genomics are helping to address this challenge. Experts from Servier and Genuity Science recently spoke on a webinar about using genomics data to drive drug development in heart failure and identify new targets for novel therapeutics. Watch this on-demand webinar to hear from these experts.
XTalks
SEPTEMBER 16, 2022
Researchers at the Francis Crick Institute and University College London in the UK have found how air pollution can trigger the activation of cells with existing genetic mutations to form cancer. In fact, one in every 600,000 cells in the lungs of a 50-year-old already contains potentially cancerous mutations. The Double Hit.
The Pharma Data
JULY 8, 2021
Today, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. Nasdaq: BIIB) and Pfizer (NYSE: PFE). Biogen Safe Harbor.
The Pharma Data
JULY 15, 2021
The access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. Nasdaq: BIIB) and Pfizer (NYSE: PFE).
Expert insights. Personalized for you.
97 
Let's personalize your content